<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02526823</url>
  </required_header>
  <id_info>
    <org_study_id>ShandongPH01</org_study_id>
    <nct_id>NCT02526823</nct_id>
  </id_info>
  <brief_title>Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma</brief_title>
  <official_title>Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Provincial Hospital</source>
  <brief_summary>
    <textblock>
      Anthracyclines were basic drugs in lymphoma treatment. However, their dose accumulation
      related cardiac toxicity limits their clinical application, especially adriamycin. Adriamycin
      has been gradually replaced by epirubicin. Polyethylene glycol liposome doxorubicin (PLD) can
      go into tumor tissues through tumor angiogenesis and produces targeted killing effect to
      tumor tissues. PLD has potential advantages in the treatment of malignant tumors,including
      lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lymphoma is one of the most rapidly growing malignant tumors in the world. It was divided
      into two major categories (Hodgkin's lymphoma (HL) and non Hodgkin's lymphoma (NHL).
      Anthracyclines were basic drugs in lymphoma treatment. However, their dose accumulation
      related cardiac toxicity limits their clinical application, especially adriamycin. Adriamycin
      has been gradually replaced by epirubicin in malignant tumor treatment because of its similar
      effects and less toxic side effects. Polyethylene glycol liposome doxorubicin (PLD) is the
      liposome formulation of doxorubicin. Methoxy Polyethylene Glycol (MPEG) contained in liposome
      surface can decrease the peak plasma levels of free drugs, extend drugs circulation time in
      blood and reduce the chance of non-specific distribution to normal tissues. PLD goes into
      tumor tissues through tumor angiogenesis and produces targeted killing effect to tumor
      tissues. PLD has potential advantages in the treatment of malignant tumors. In lymphoma
      patients' therapy, the clinical application of PLD is expected to be a new method. Therefore,
      the investigators designed the randomized controlled clinical study and aimed to compare the
      efficacy and safety between PLD and epirubicin in primary B-NHL, peripheral T-cell lymphoma
      (PTCL) and HL patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">February 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with complete remission （CR）</measure>
    <time_frame>After two 21-day or 28-day courses, up to 42 to 56 days.</time_frame>
    <description>Sum of products of greatest diameters （SPD）was used to evaluate the therapy effect.Number of participants with CR was assessed by Cheson Standard.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Lymphoma, Non-Hodgkin;Hodgkin Disease</condition>
  <arm_group>
    <arm_group_label>R-CHOP/CHOPE or ABVD chemotherapy regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>R-CHOP/CHOPE every 21 days or ABVD every 28 days for total 6 courses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-CDOP/CDOPE or DBVD chemotherapy regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R-CDOP/CDOPE every 21 days or DBVD every 28 days for total 6 courses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP/CHOPE or ABVD chemotherapy regimen</intervention_name>
    <description>R-CHOP:
Rituximab：375mg/m2，ivgtt，D0； Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；
CHOPE:
Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;
ABVD:
Epirubicin：35 mg/m2，ivgtt，D1、15； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；</description>
    <arm_group_label>R-CHOP/CHOPE or ABVD chemotherapy regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CDOP/CDOPE or DBVD chemotherapy regimen</intervention_name>
    <description>R-CDOP:
Rituximab：375mg/m2，ivgtt，D0； PLD 30-40 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；
CDOPE:
PLD 30-40 mg/m2，ivgtt，D1； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;
DBVD:
PLD 15-20 mg/m2，ivgtt，D1； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；</description>
    <arm_group_label>R-CDOP/CDOPE or DBVD chemotherapy regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Primary B-NHL, PTCL (ALK+ anaplastic large cell lymphoma and NK(natural killer cell
             )/T cell lymphoma were excluded) or HL patients confirmed by histopathology;

          2. Ages ≥18 years old, &lt; 80 years old;

          3. ECOG (Eastern Cooperative Oncology Group）score: 0-2

          4. At least one measurable lesion;

          5. Expected survival time≥3 months;

          6. Liver function: transaminase≤2.5× upper limit of normal value，bilirubin≤1.5×upper
             limit of normal value;

          7. Renal function: serum creatinine is 44-133 mmol/L;

          8. Routine blood test：WBC≥3.0×109/L，Neutrophils≥1.5×109/L，Hb≥100g/L，Platelet≥80×109/L；
             LVEF≥50%;

          9. New York Heart Association (NYHA) heart function classification is I-II grade

         10. signed informed consent.

        Exclusion Criteria:

          1. Patients with severe complications or severe infection;

          2. Invasion of central nervous system;

          3. Patients with severe heart disease history, including ventricular tachycardia (VT),
             atrial fibrillation (AF), heart block, myocardial infarction (MI), congestive heart
             failure (CHF), coronary heart disease patients needed therapy;

          4. patients with severe allergic constitution, or those who are allergic to or intolerant
             of drug composition in chemotherapy regimens; with other malignant tumors in the past
             5 years;

          5. patients received doxorubicin therapy, total cumulative dose of adriamycin was more
             than 300 mg/m2, total cumulative dose of epirubicin was more than 450 mg/m2;

          6. Patients participate in other clinical studies;

          7. Other patients who are not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Hematology, Provincial Hospital Affiliated to Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Wang, MD, PHD</last_name>
      <phone>+86-531-68778331</phone>
      <email>xinw007@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Lili Feng, MD</last_name>
      <phone>+86-531-68776358</phone>
      <email>fenglili1982624@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lotrionte M, Biondi-Zoccai G, Abbate A, Lanzetta G, D'Ascenzo F, Malavasi V, Peruzzi M, Frati G, Palazzoni G. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013 Dec 15;112(12):1980-4. doi: 10.1016/j.amjcard.2013.08.026. Epub 2013 Sep 25. Review.</citation>
    <PMID>24075281</PMID>
  </reference>
  <reference>
    <citation>Italian Multicentre Breast Study with Epirubicin, Ambrosini G, Balli M, Garusi G, Demicheli R, Jirillo A, Bonciarelli G, Bruscagnin G, Fila G, Bumma C, Lacroix F, Buzzi F, Di Costanzo F, Padalino D, Brugia M, Calabresi F, Natali M, Cartei G, Chiesa G, Blasina B, Ciambellotti E, Moro G, D'Aquino S, Altavilla G, Adamo V, De Maria D, Falchi AM, Bertoncelli P, Farris A, Fiorentino M, Fornasiero A, Fosser V, Daniele O, Foggi CM, Speranza GB, Sartori S, Camilluzzi E, Gallo L, Poggio R, Secondo V, Gambi A, Grignani F, Capodicasa E, Lopez M, Papaldo P, Di Lauro L, Vici P, Marenco G, Folco U, Bonanni F, Marsilio P, Palazzotto G, Di Carlo A, Cusimano MP, Pastorino G, Puccetti C, Giusto M, Rausa L, Gebbia N, Palmeri S, D'Alessandro N, Saccani F, Becchi G, Schieppati G, Spinelli I, Tagliagambe A, Tonato M, Minotti V, Ardia A, Viaro D, De Micheli P, Zingali G, Sacchetti G, Intini C. Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. J Clin Oncol. 1988 Jun;6(6):976-82.</citation>
    <PMID>2897433</PMID>
  </reference>
  <reference>
    <citation>Bai B, Huang HQ, Cai QQ, Wang XX, Cai QC, Lin ZX, Gao Y, Xia Y, Bu Q, Guo Y. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma. Med Oncol. 2013 Mar;30(1):350. doi: 10.1007/s12032-012-0350-5. Epub 2013 Jan 18.</citation>
    <PMID>23329307</PMID>
  </reference>
  <reference>
    <citation>Clozel T, Deau B, Benet C, Franchi P, Robin M, Madelaine I, Thieblemont C, de Kerviler E, Brière J, Brice P. Pegylated liposomal doxorubicin: an efficient treatment in patients with Hodgkin lymphoma relapsing after high dose therapy and stem cell transplation. Br J Haematol. 2013 Sep;162(6):846-8. doi: 10.1111/bjh.12428. Epub 2013 Jun 24.</citation>
    <PMID>23789905</PMID>
  </reference>
  <reference>
    <citation>Schmitt CJ, Dietrich S, Ho AD, Witzens-Harig M. Replacement of conventional doxorubicin by pegylated liposomal doxorubicin is a safe and effective alternative in the treatment of non-Hodgkin's lymphoma patients with cardiac risk factors. Ann Hematol. 2012 Mar;91(3):391-7. doi: 10.1007/s00277-011-1308-y. Epub 2011 Aug 18.</citation>
    <PMID>21850390</PMID>
  </reference>
  <reference>
    <citation>Fan Y, Lin NM, Luo LH, Fang L, Huang ZY, Yu HF, Wu FQ. Pharmacodynamic and pharmacokinetic study of pegylated liposomal doxorubicin combination (CCOP) chemotherapy in patients with peripheral T-cell lymphomas. Acta Pharmacol Sin. 2011 Mar;32(3):408-14. doi: 10.1038/aps.2010.217.</citation>
    <PMID>21372831</PMID>
  </reference>
  <reference>
    <citation>Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol. 2012 Apr 23;1(1):10. doi: 10.1186/2162-3619-1-10.</citation>
    <PMID>23210520</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2015</study_first_submitted>
  <study_first_submitted_qc>August 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2015</study_first_posted>
  <last_update_submitted>April 17, 2016</last_update_submitted>
  <last_update_submitted_qc>April 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Wang Xin</investigator_full_name>
    <investigator_title>Director of Department of Hematology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

